246 related articles for article (PubMed ID: 28704852)
1. Pregnancy and Tumor Outcomes in Women with Prolactinoma.
Araujo B; Belo S; Carvalho D
Exp Clin Endocrinol Diabetes; 2017 Nov; 125(10):642-648. PubMed ID: 28704852
[No Abstract] [Full Text] [Related]
2. [Prolactinoma and pregnancy].
Trifonov I
Akush Ginekol (Sofiia); 2004; 43 Suppl 2():16-22. PubMed ID: 15518268
[No Abstract] [Full Text] [Related]
3. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
Lebbe M; Hubinont C; Bernard P; Maiter D
Clin Endocrinol (Oxf); 2010 Aug; 73(2):236-42. PubMed ID: 20455894
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy.
Rastogi A; Bhadada SK; Bhansali A
Gynecol Endocrinol; 2017 Apr; 33(4):270-273. PubMed ID: 27908214
[TBL] [Abstract][Full Text] [Related]
5. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation.
Auriemma RS; Perone Y; Di Sarno A; Grasso LF; Guerra E; Gasperi M; Pivonello R; Colao A
J Clin Endocrinol Metab; 2013 Jan; 98(1):372-9. PubMed ID: 23162092
[TBL] [Abstract][Full Text] [Related]
6. Prolactinoma and pregnancy: From the wish of conception to lactation.
Maiter D
Ann Endocrinol (Paris); 2016 Jun; 77(2):128-34. PubMed ID: 27130071
[TBL] [Abstract][Full Text] [Related]
7. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
8. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
9. An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists.
O'Sullivan SM; Farrant MT; Ogilvie CM; Gunn AJ; Milsom SR
Aust N Z J Obstet Gynaecol; 2020 Jun; 60(3):405-411. PubMed ID: 31583693
[TBL] [Abstract][Full Text] [Related]
10. Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center.
Prencipe N; Bona C; Cuboni D; Berton AM; Bioletto F; Varaldo E; Aversa LS; Sibilla M; Gasco V; Ghigo E; Grottoli S
Pituitary; 2024 Jun; 27(3):269-276. PubMed ID: 38499816
[TBL] [Abstract][Full Text] [Related]
11. Prolactinoma and pregnancy - a series of cases including pituitary apoplexy.
Galvão A; Gonçalves D; Moreira M; Inocêncio G; Silva C; Braga J
J Obstet Gynaecol; 2017 Apr; 37(3):284-287. PubMed ID: 27866462
[TBL] [Abstract][Full Text] [Related]
12. Management of prolactinomas during pregnancy.
Witek P; Zieliński G
Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103
[TBL] [Abstract][Full Text] [Related]
13. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
14. Clinical practice. Prolactinomas.
Klibanski A
N Engl J Med; 2010 Apr; 362(13):1219-26. PubMed ID: 20357284
[No Abstract] [Full Text] [Related]
15. Dopamine receptor agonists for treating prolactinomas.
Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
[TBL] [Abstract][Full Text] [Related]
16. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Rains CP; Bryson HM; Fitton A
Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
[TBL] [Abstract][Full Text] [Related]
17. Cabergoline treatment of pregnant women with macroprolactinomas.
Laloi-Michelin M; Ciraru-Vigneron N; Meas T
Int J Gynaecol Obstet; 2007 Oct; 99(1):61-2. PubMed ID: 17602689
[No Abstract] [Full Text] [Related]
18. Prolactinoma in pregnancy.
Molitch ME
Best Pract Res Clin Endocrinol Metab; 2011 Dec; 25(6):885-96. PubMed ID: 22115164
[TBL] [Abstract][Full Text] [Related]
19. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
20. High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy.
Banerjee A; Wynne K; Tan T; Hatfield EC; Martin NM; Williamson C; Meeran K
Clin Endocrinol (Oxf); 2009 May; 70(5):812-3. PubMed ID: 18803677
[No Abstract] [Full Text] [Related]
[Next] [New Search]
